Tharimmune announces option agreement for key technologies for generating her2/her3 antibody drug conjugates (adcs)

Obtained rights from washington university to develop and incorporate human her2 directed antibodies complements early pipeline of novel tunable "knob domain" antibodies for her2 & her3 bridgewater, nj / accesswire / april 23, 2024 / tharimmune, inc. (nasdaq:thar) ("tharimmune" or the "company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation & immunology, announced today an option agreement for an exclusive license with washington university in st. louis for the rights to develop and commercialize technology related to multiple hybridomas and antibodies directed specifically towards human her2. the technology was developed through a collaboration of multidisciplinary researchers in cancer immunology at washington university school of medicine.
THAR Ratings Summary
THAR Quant Ranking